Phio Pharmaceuticals to Present at the Life Sciences Future Conference

Core Insights - Phio Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to combat cancer [1][4] - The company will present updates on its ongoing Phase 1b clinical trial for its lead product candidate PH-762 at the Life Sciences Future Conference on September 25-26, 2025 [1][2] Company Overview - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is advancing its INTASYL® gene silencing technology, particularly in the field of immuno-oncology [4] - The lead clinical program, PH-762, targets the PD-1 gene associated with various skin cancers, including cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma [4] - The ongoing Phase 1b trial (NCT 06014086) is evaluating PH-762 as a potential non-surgical treatment for skin cancers [4] Conference Details - The presentation by Mr. Robert Bitterman, President and CEO, will include updates on the Phase 1b clinical trial and future strategies for the PH-762 development program [2] - The Life Sciences Future Conference will take place at the Sheraton Valley Forge Hotel in King of Prussia, PA, on September 25-26, 2025 [3]